PROTECmo Study: Thrombocytopenia in VenoVenous ECMO Linked to High Bleeding Risk
Marta Velia Antonini, Hematologist, Perfusionist ECMO and NRP Specialist and Chair of the Normothermic Regional Perfusion EuroELSO Working Group, shared on X:
”Thrombocytopenia in VV ECMO? Highly prevalent in VV ECMO, and strongly associated with bleeding risk and reduced survival.
Platelet transfusions do not appear to significantly reduce bleeding risk: targeted prevention strategies needed!
- Adults with respiratory failure; baseline thrombocytopenia 27.9%, mild 14.7%, moderate 8.7%, severe 4.4%
- Thrombocytopenia in ECLS occurred at least once in 80.2%; mild 21.3%, moderate 32.2%, severe 26.7%
- Mild thrombocytopenia increased risk of bleedings by 61%; moderate and severe by 90%
- Risk for thrombocytopenia increased with ICU days prior to ECMO, postop admission, immunocompromised state, RRT, septic shock, low hemoglobin, circuit replacement.”
Read the full article in Critical Care.
Title: Incidence, kinetics, and clinical impact of thrombocytopenia in venovenous ECMO: insights from the multicenter observational PROTECMO study
Authors: Nina Buchtele, Kenichi Tanaka, Fabio Tuzzolino, Cara Agerstrand, Ali Ait Hssain, Jordi Riera, Peter Schellongowski, Matthieu Schmidt, Raj Ramanan, Martin Balik, Lars Mikael Broman, Nicolo Rizzitello, Konstanty Szułdrzyński, Whitney D. Gannon, Vito Fanelli, Brian Trethowan, Hergen Buscher, Huda Alfoudri, Marco Giani, Alain Combes, Giacomo Grasselli, Roberto Lorusso, Antonio Arcadipane, Daniel Brodie, Gennaro Martucci, PROTECMO Study group

Stay updated on all science in the field of hematology with Hemostasis Today.
-
Jan 9, 2026, 12:17Louise St Germain Bannon Invites You to Self-Nominate for the ISTH Council
-
Jan 9, 2026, 09:25Emma Groarke Shares A Comprehensive Review on VEXAS Syndrome
-
Jan 9, 2026, 09:13Anirban Sen Gupta Presents PlateChek
-
Jan 9, 2026, 08:58Oscar Pena Shares KDIGO 2026 Update: 5 Critical Changes for Anemia in CKD Management
-
Jan 9, 2026, 07:38Bartosz Hudzik on Subacute Coronary Occlusions: Navigating the Gray Zone in CAD Care
-
Jan 9, 2026, 07:27Gregory Piazza on The Role of D-Dimer in VTE Evaluation
-
Jan 9, 2026, 07:19Emmanuel J Favaloro Shares the 1st Article in a VWD Series Marking the 100-Year Anniversary
-
Jan 9, 2026, 07:07Taylor Robichaux on Recombinant ADAMTS13 Therapy in cTTP
-
Jan 9, 2026, 06:25Sara Ng: VTE Continues to Plague Modern Oncology
